Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30329, USA.
Department of Pharmacology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Cell Rep. 2018 Jan 23;22(4):941-952. doi: 10.1016/j.celrep.2017.12.095. Epub 2018 Jan 28.
Dopamine (DA) loss in Parkinson's disease (PD) alters the function of striatal projection neurons (SPNs) and causes motor deficits, but DA replacement can induce further abnormalities. A key pathological change in animal models and patients is SPN hyperactivity; however, the role of glutamate in altered DA responses remains elusive. We tested the effect of locally applied AMPAR or NMDAR antagonists on glutamatergic signaling in SPNs of parkinsonian primates. Following a reduction in basal hyperactivity by antagonists at either receptor, DA inputs induced SPN firing changes that were stable during the entire motor response, in clear contrast with the typically unstable effects. The SPN activity reduction over an extended putamenal area controlled the release of involuntary movements in the "on" state and therefore improved motor responses to DA replacement. These results demonstrate the pathophysiological role of upregulated SPN activity and support strategies to reduce striatal glutamate signaling for PD therapy.
帕金森病(PD)中的多巴胺(DA)丧失改变了纹状体投射神经元(SPN)的功能,并导致运动缺陷,但 DA 的替代会引起进一步的异常。在动物模型和患者中,一个关键的病理变化是 SPN 的过度活跃;然而,谷氨酸在改变的 DA 反应中的作用仍然难以捉摸。我们测试了局部应用 AMPAR 或 NMDAR 拮抗剂对帕金森猴 SPN 中谷氨酸能信号的影响。在两种受体的拮抗剂降低基础过度活跃后,DA 输入诱导 SPN 放电变化,在整个运动反应过程中保持稳定,与通常不稳定的影响形成鲜明对比。在扩展的壳核区域内的 SPN 活动减少控制了“开启”状态下不自主运动的释放,从而改善了对 DA 替代的运动反应。这些结果表明了上调的 SPN 活性的病理生理作用,并支持了减少纹状体谷氨酸信号传递的策略,以用于 PD 治疗。